Why Moderna, Inc. (MRNA) stock moved
Moderna, Inc. (MRNA) shares climbed 12.3% to $172.94 as of September 22, 2026, a sharp gain from the prior close of $154.04. BestStocks flagged the session as a major change for MRNA. Below, we break down what changed for MRNA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
MRNA climbed 12.3% to $172.94
MRNA climbed 12.3% in its latest session, moving from $154.04 to $172.94.
What it means for Moderna, Inc. investors
For Moderna, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Strong 12.3% price move with conviction; Positive price momentum. Weighing against that: Moderna reversed sharply after a historic surge driven by positive cancer-vaccine data, with the stock down 22.22% to $135.63 as a short squeeze unwind and profit-taking erased gains (Benzinga); MRNA moved -6.40% from its $57.54 open to a $53.86 close on 2026-08-06. Wall Street's consensus price target sits at $115.70, implying -33.1% downside from $172.94. Over the past 90 days analysts logged 3 upgrades and 1 downgrade. BestStocks rates the overall signal quality medium (63/100). With earnings roughly 44 days out, the next report is the most likely near-term test of the move.
MRNA price reaction
MRNA last traded at $172.94, up $18.90 (+12.27%) from the previous close of $154.04. The session traded on 1.5× average volume (above avg), so the move carried above-average conviction.
Bullish and bearish analyst opinions on Moderna, Inc. (MRNA)
The consensus analyst price target on Moderna, Inc. (MRNA) is $115.70, 33.1% below the recent $172.94. Over the past 90 days analysts logged 3 upgrades, 11 maintains, and 1 downgrade. Here is how the bullish and bearish cases on MRNA line up.
The bullish case
- The Street's most bullish target is $245.00 (+41.7%).
- 3 analyst upgrades in the past 90 days, most recently Argus Research to Buy (2026-08-28).
- Strong 12.3% price move with conviction.
- Positive price momentum.
- Moderna surged +9.08% to $149.02 following investor enthusiasm over successful late-stage clinical trial results for its personalized mRNA cancer vaccine developed with Merck, which showed high effectiveness in preventing recurrence in high-risk melanoma patients (Yahoo Finance).
The bearish case
- The consensus analyst price target of $115.70 sits 33.1% below the recent $172.94, so the average target sees limited room to run.
- The most bearish analyst target is $25.00 (-85.5%).
- 1 analyst downgrade in the past 90 days, most recently Rothschild & Co to Sell (2026-09-03).
- Moderna reversed sharply after a historic surge driven by positive cancer-vaccine data, with the stock down 22.22% to $135.63 as a short squeeze unwind and profit-taking erased gains (Benzinga).
- MRNA moved -6.40% from its $57.54 open to a $53.86 close on 2026-08-06.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 22, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MRNA
Frequently asked questions about MRNA
Why did Moderna, Inc. (MRNA) stock move?
MRNA climbed 12.3% to $172.94. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did MRNA stock rise?
MRNA gained 12.27% ($18.90) versus the prior close of $154.04, last trading at $172.94 on 1.5× average volume.
When is Moderna, Inc.'s next earnings date?
MRNA's next earnings report is estimated for 2026-11-05 — about 44 days away.
What is the analyst price target for MRNA?
The consensus analyst price target for MRNA is $115.70, about 33.1% below the current $172.94. Over the past 90 days, analysts recorded 3 upgrades, 11 maintains, and 1 downgrade.
How BestStocks tracks MRNA
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MRNA-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MRNA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 22, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
